New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
08:01 EDTBIND, AMGNBIND Therapeutics maintained as an Outperform, says Credit Suisse
Amgen (AMGN) declined to exercise its option on BIND Therapeutics' Accurin technology following completion of the collaboration. Credit Suisse does not view this as a negative read through for BIND-014 and continues to believe the technology is a valuable platform and expects Ph II results for BIND-014 in 2H 2014 to be a catalyst. The firm maintains its Outperform rating but lowers its price target to $20 from $21.
News For BIND;AMGN From The Last 14 Days
Check below for free stories on BIND;AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
07:30 EDTAMGNSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 29, 2014
07:26 EDTAMGNInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
08:59 EDTAMGNSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
08:11 EDTAMGNAmgen to host conference call
Subscribe for More Information
September 22, 2014
09:02 EDTAMGNAmgen submits BLA to the FDA for immunotherapy blinatumomab
Subscribe for More Information
September 17, 2014
08:03 EDTAMGNAmgen price target raised to $151 from $143 at Morgan Stanley
Morgan Stanley raised Amgen's price target to $151 based on increased brodalumab and AMG 416 expectations. Shares are Overweight rated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use